← All trials
NCT01539304
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2010
- Primary completion
- Aug 1, 2011
- Completion date
- Sep 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 245
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- SamA Pharmaceutical Co., LtdLead sponsor
- Inha UniversityOverall official - principal investigator
- Hanyang UniversityOverall official - principal investigator
- Sungkyunkwan UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
- Kyung Hee UniversityOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Soonchunhyang UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.